This document discusses purification, purity analysis, and impurity analysis solutions for pharmaceutical research and development, aiming to achieve effective pharmaceutical production. These three key areas - purification, purity analysis, and impurity analysis - are essential for the future success of the pharmaceutical industry and offer the potential to increase productivity and facilitate regulatory compliance.
Agilent provides comprehensive solutions to address challenges in the pharmaceutical industry, specifically focusing on increasing productivity and ensuring regulatory compliance. The document highlights three key areas: purification, purity analysis, and impurity analysis.
For purification, Agilent offers systems ranging from small-scale flash chromatography for medicinal chemists to large-scale preparative liquid chromatography (LC) for process chemists. For purity analysis, the company provides various LC, GC, CE, SFC, and MS systems tailored for discovery, development, and manufacturing phases. Impurity analysis solutions cover organic impurities, heavy metal impurities, and residual solvents using specific instrumentation like ICP-MS and GC/MS.
| Flash Purification System Model | 971-FP |
|---|---|
| Analytical SFC and Quality Testing Services Model | 7100 Capillary Electrophoresis Systems |
| Organic Impurity Analysis LC/MS System | 1200 Infinity Series LC and 6500 Series Accurate-Mass Q-TOF LC/MS Systems |
| Heavy Metal Impurity Analysis System | 7700 Series ICP-MS System |
| Residual Solvent Analysis GC System | 7890A GC System with 7697A Headspace Sampler and 5975C Series GC/MSD System |
The three key areas are purification, purity analysis, and impurity analysis.
These solutions are designed to purify synthesized compounds to ensure target compound purity, which impacts the ability to progress from hit to viable drug candidate.